Lymphomas marginal zone lymphoma

Mantle cell lymphoma, marginal zone lymphoma... 

B-ALL, Burkitt s lymphoma, mantle cell lymphoma, marginal zone lymphoma,... 

In the first dose escalating and exploratory phase 1 study, ibrutinib showed antitumor activity in multiple B-ceU cancers. 56 patients with relapsed/refractory CLL/SLL and B-cell NHLs, such as MCL, folhcular lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, and WM, were enrolled. The overall response rate was 60%, including 16% complete response. The median progression-free survival was 13.6 months and most adverse events were grades 1 and 2. Btk was completely occupied at doses 2.5 mg/kg and above as demonstrated by probe (2) competition assay of peripheral blood mononuclear cell samples collected from patients. 

L Splenic marginal zone lymphoma (SMZL). These tumors involve both the white and the red pulp of the spleen. In the white pulp the neoplastic cells surround or replace the germinal centers, often with effacement of the mantle cell zone, and infiltrate the marginal zone. In the red pulp the tumor cells form nodules and sheets and infiltrate the sinuses. The neoplastic lymphocytes may circulate and involve the bone marrow (H5,19). 

A2. Nodal marginal zone lymphoma (MZL). These tumors may show a variable pattern of lymph node infiltration including parafollicular, perisinusal, nodular, and diffuse. Residual reactive follicles may show infiltration by the neoplastic cell population (S30). 

B2. Bailey, E. M., Ferry, J. A., Harris, N. L., Mihm, M. C., Jr., Jacobson, J. O., and Duncan, L. M., Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue A study of 15 patients. Am. J. Surg. Pathol. 20,1011-1023 (1996). 

C4. Campo, E., Miquel, R., Krenacs, L., Sorbara, L., Raffeld, M., and Jaffe, E. S., Primary nodal marginal zone lymphomas of splenic and MALT type. Am. J. Surg. Pathol. 23, 59-68 (1999). 

M26. Mollejo, M., Lloret, E., Menarguez, J., Piris, M. A., and Isaacson, P. G., Lymph node involvement by splenic marginal zone lymphoma Morphological and immunohistochemical features. Am. J. Surg. Pathol. 21, 772-780 (1997). 

R9. Remstein, E. D., James, C. D., and Kurtin, P. J., Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am. J. Pathol. 156,1183-1188 (2000). 

Tefferi A, Hanson CA, Kurtin PJ, Katzmatm JA, Dalton RJ, Nichols WL. Acquired von Willebrand s disease due to d>errant expression of platdd glycoprotein lb by marginal zone lymphoma cdls. Br J Haematol 1997 96 850-3. 

CD 11c is a type I transmembrane protein that is expressed on monocytes, granulocytes, a subset of B cells, dendritic cells, and macrophages and may be demonstrated on B-cell chronic lymphocytic leukemia, marginal zone lymphomas, and hairy cell leukemia. The amount of this antigen is varied with the antigen having dim to partial expression on chronic lymphocytic leukemia and a bright expression on hairy cell leukemia. CD 11c is abundantly expressed... 

CD20 and BCL-2 mark mantle cell, follicular, and some marginal zone lymphomas along with B-CLL/SLL. 

Lai R, Arber DA, Chang KL, et al. Frequency of bcl-2 expression in non-Hodgkin s lymphoma a smdy of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol. 1998 ll(9) 864-869. 

Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin He-matol. 1999 36(2) 148-154. 

Savilo E, Campo E, Mollejo M, et al. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Mod Pathol. 1998 ll(7) 601-606. 

Baldassano MF, Bailey EM, Ferry JA, et al. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma comparison of morphologic and immunophenotypic features. Am J Surg Pathol. 1999 23 88-96. 

---